CAS 50-65-7 Niclosamide - CAS 50-65-7 - Analytical Products / Alfa Chemistry

CAT	AP50657
CAS	50-65-7
Structure
Molecular Weight	327.12

Description	A salicylanilide anthelmintic drug that acts as a potent and selective Stat3- and Wnt-signaling pathway inhibitor.
Solubility	DMSO: 2.5 mg/mL; ethanol: 5 mg/mL
Assay	≥97% (HPLC)
Color	pale yellow
Form	solid; protect from light
Size	1MG
Storage Conditions	+2C to +8C

[The Vibrio-Static Test With Niclosamide to Identify Bacteria of Genus Vibrio]

E P Sivolodskiy

Klin Lab Diagn. 2014 May;(5):53-5.

PMID: 25338465

Synthesis and Orally Macrofilaricidal Evaluation of Niclosamide Lymphotropic Prodrugs

L Elkihel, P M Loiseau, J Bourass, P Gayral, Y Letourneux

Arzneimittelforschung. 1994 Nov;44(11):1259-64.

PMID: 7848342

* Products or Services Interested: Niclosamide - CAS 50-65-7 (50-65-7)
* Your question
* Name
* Email
Verification Code

Case Study

Niclosamide Used for Multi-Pathway Modulation in Amyotrophic Lateral Sclerosis (ALS) Models

Milani, Martina, et al. Neurotherapeutics 21.3 (2024): e00346.

Niclosamide, a long-established anthelmintic drug recognized by the WHO as an essential medicine, has recently garnered attention for its potent anti-inflammatory and anti-fibrotic effects. In the context of neurodegenerative disorders, particularly Amyotrophic Lateral Sclerosis (ALS), niclosamide shows promise for therapeutic repurposing due to its ability to target multiple dysregulated molecular pathways, including STAT3 and mTOR signaling.
In a recent study, niclosamide was administered intraperitoneally at symptom onset to two transgenic ALS murine models: SOD1-G93A and FUS mice. These models represent distinct genetic underpinnings of ALS pathology. Disease progression was evaluated using neurological scoring, rotarod performance, wire-hanging tests, and survival analysis. The results demonstrated that niclosamide significantly delayed disease progression and extended survival. Histopathological assessments further revealed reduced gliosis, preservation of motor neurons, decreased muscle atrophy, and suppression of neuroinflammatory responses in both spinal cord and muscle tissues.
These findings underscore niclosamide's capacity to exert a multi-targeted neuroprotective effect, modulating several critical pathways implicated in ALS pathogenesis. This positions niclosamide as a compelling candidate for repurposing in ALS therapy, especially within combination treatment strategies aimed at simultaneously correcting various molecular defects. As a versatile modulator of cellular stress and inflammation, niclosamide represents a promising approach to managing complex neurodegenerative diseases like ALS, warranting further clinical investigation.

Niclosamide Used for the Prevention of Frailty and Age-Associated Muscle Decline

Choi, Pyeong Geun, et al. Journal of Advanced Research (2025).

Niclosamide, a clinically approved anthelmintic agent known for its autophagy-promoting capabilities, has recently emerged as a potential therapeutic candidate for age-related frailty. In this study, its anti-aging effects were systematically evaluated using Caenorhabditis elegans and murine aging models, focusing on physical performance, metabolic integrity, and muscle preservation.
Administered in both model systems, niclosamide significantly improved physical function and metabolic health. In C. elegans, niclosamide treatment extended lifespan and ameliorated frailty-associated phenotypes. In aging mice, it notably mitigated muscle atrophy and enhanced locomotor activity. Mechanistically, niclosamide suppressed the muscle degradation pathway mediated by the ubiquitin-proteasome system, which is often upregulated by hyperactivation of the mammalian target of rapamycin complex 1 (mTORC1). Simultaneously, it enhanced autophagic flux, contributing to improved proteostasis in aged muscle tissues
Transcriptomic analysis (mRNA-seq) further confirmed that niclosamide modulates metabolism-related pathways, reinforcing its potential to correct age-associated metabolic dysfunction. These findings establish niclosamide as a multifunctional agent that not only targets key mechanisms underlying muscle aging but also promotes systemic healthspan extension.
In summary, niclosamide is used for the prevention of frailty through modulation of mTORC1 signaling, proteostasis enhancement, and metabolic regulation, representing a promising repurposing opportunity in geriatric medicine and anti-aging interventions.

Niclosamide Used for the Synthesis of Novel Sulfonamide Analogs via Successive Paired Electrolysis

Rezaei, Haniya, et al. RSC advances 15.22 (2025): 17803-17810.

Niclosamide, a salicylanilide-based oral anthelmintic, is increasingly explored in medicinal chemistry due to its broad-spectrum bioactivity, including anticancer and antiviral properties. However, its poor oral bioavailability and inherent cytotoxicity pose limitations to its therapeutic repurposing. In response, structural modification through green synthetic methodologies has emerged as a promising strategy to enhance its pharmacological profile.
In this study, novel niclosamide analogs were synthesized via a successive paired electrolysis approach using arylsulfinic acids as nucleophiles. This electrochemical transformation exploits the redox behavior of niclosamide-reducible at the cathode and oxidizable at the anode-allowing it to undergo selective functionalization without the use of catalysts, chemical oxidants, or reductants.
The resulting compound, 5-chloro-N-(2-chloro-4-(phenylsulfonamido)phenyl)-2-hydroxybenzamide, features a sulfonamide moiety incorporated into the niclosamide framework. This one-pot, green electrochemical method proceeds under mild conditions and represents an efficient route for generating structurally novel analogs with potentially improved pharmacological profiles.
This case highlights the utility of niclosamide as a precursor for the electrosynthetic preparation of new drug candidates. The electrochemical method not only aligns with sustainable chemistry principles but also opens avenues for expanding the chemical space of salicylanilide derivatives in drug discovery.